168-LB: Latent Autoimmune Diabetes in Youth (15–29 Years Old): the Heavier End of an Autoimmune Disease Spectrum

JIN CHENG,XIAOHAN TANG,XIANG YAN,SHUOMING LUO,XIA LI,ZHIGUANG ZHOU
DOI: https://doi.org/10.2337/db21-168-lb
IF: 7.7
2021-01-01
Diabetes
Abstract:Context: Latent autoimmune diabetes in youth (LADY) falls in a grey zone of the current diabetes scheme due to the lack of established definition and diagnosis criteria. Objective: To investigate the prevalence and clinical features of LADY patients between 15-29 years old as a component of an age-related continuous diabetes spectrum. Methods: This nationwide, multi-center, cross-sectional study included 1803 newly diagnosed diabetic youth of 15-29 years old across China from April 2015 to October 2017. Glutamic acid decarboxylase autoantibody (GADA) was screened in 1508 phenotypic T2DM subjects and those with positive GADA were defined as LADY. Metabolic status, insulin resistance and residual β-cell function of LADY were investigated and compared with other 658 adult-onset latent autoimmune diabetes (LADA) patients enrolled at the same time. The age-related characteristics of the latent autoimmune diabetes spectrum were explored. Results: LADY accounted for 7.9% (119/1508) of the phenotypic T2DM youth. Compared with GADA-negative T2DM youth, LADY patients had better metabolic control, less insulin resistance, and lower levels of β-cell function, which were closely related to their GADA levels (all P < 0.05). After stratifying LADA patients according to their age of onset, the GADA level decreased across the LADY, ‘Y-LADA’ (young LADA, age of onset <60 years old) and ‘E-LADA’ (elderly LADA, age of onset ≥60 years old) groups, with the prevalence of metabolic syndrome, levels of insulin resistance and residual β-cell function presenting an increasing trend (all P <0.05). Conclusions: A high prevalence of LADY exist in phenotypic T2DM youth. The latent autoimmune diabetes occurred at different ages formed a continuous clinical spectrum from LADY to LADA, in which the LADY patients carried heavier autoimmune load. Disclosure J. Cheng: None. X. Tang: None. X. Yan: None. S. Luo: None. X. Li: None. Z. Zhou: None. Funding National Science and Technology Infrastructure Program (2013BAI09B12, 2015BAI12B13); National Key R&D Program of China (2016YFC1305000, 2017YFC1309604)
What problem does this paper attempt to address?